Two Chinese COVID-19 medicines receive emergency approval
The National Medical Products Administration (NMPA) has given emergency approval to the registration application of two COVID-19 medicines, BRII-196 and BRII-198. This is China’s first approved COVID-19 virus-neutralizing antibody combination therapy with independent intellectual property rights. The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and … Read more